Vinayak Ramanath, MD
Nephrology · Lagrange, GANPI 1356571079
Payments from drug & device makers
Across 375 payments — averaging $8145.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$1.2M
- Vertex$854K
- AstraZeneca$527K
- Alnylam Pharmaceuticals Inc.$150K
- Boehringer Ingelheim$140K
- Merck$49K
- plus $135K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 71 | $1,198,930 |
| Vertex | 7 | $854,440 |
| AstraZeneca(2 entities) | 40 | $527,354 |
| Alnylam Pharmaceuticals Inc. | 44 | $149,538 |
| Boehringer Ingelheim | 9 | $139,772 |
| Merck | 2 | $49,368 |
| Akebia Therapeutics Inc | 79 | $47,103 |
| Astrazeneca UK Limited | 3 | $31,475 |
| Bayer | 34 | $23,292 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22,276 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 7 | $3,130 |
| Novartis | 7 | $3,120 |
| Boehringer Ingelheim Limited | 3 | $1,878 |
| Ardelyx, Inc. | 6 | $1,620 |
| Baxter Healthcare | 7 | $273 |
| Travere Therapeutics, Inc. | 21 | $174 |
| Amgen(2 entities) | 5 | $173 |
| Mallinckrodt Hospital Products Inc. | 3 | $142 |
| Valeritas, Inc. | 1 | $90 |
| GSK | 5 | $82 |
| Amarin Pharma, Inc. | 1 | $81 |
| Novo Nordisk | 4 | $63 |
| Medtronic | 1 | $61 |
| Fresenius USA Marketing, Inc. | 3 | $51 |
| OPKO Pharmaceuticals, LLC | 3 | $45 |
| Aurinia Pharma U.S., Inc. | 2 | $41 |
| Cormedix Inc. | 1 | $34 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Vifor Pharma, Inc. | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Neurelis, Inc. | 1 | $17 |
| Boehringer Ingelheim International GmbH | 1 | $1 |
How this compares
$3,054,692 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Lagrange
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Harold HubertAugusta$2.8M
- Tamorie SmithColumbus$1.9M
- Barton BrezinaAugusta$1.5M
- Frederic Rahbari OskouiAtlanta$1.5M
- Rajeev ChauhanColumbus$1.1M
- Sagar PanseMacon$1.1M
- Laura MulloyAugusta$891K
- Matthew DiamondAugusta$815K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.